Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase
Observational
Started
2021-06-01
Last updated
2023-01-31
Condition(s) studied
Immunoglobulin Light Amyloidosis Cardiomyopathy
Investigational drug(s) / intervention(s)
current treatment of AL-CM
current treatment of AL-CM: current treatment of AL-CM
Study summary
In this study, patients diagnosed with Al-CM were selected to observe the effect of treatment and conduct long-term follow-up.
Eligibility
Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria:
* Patients aged 18-90 years, regardless of gender, diagnosed with Al-CM at the Second Affiliated Hospital of Zhejiang University School of Medicine;
* Patients have the ability to understand the test, can cooperate with investigators.
Exclusion Criteria:
* Unable to understand or unwilling to fill in informed consent forms or follow visitors
Primary outcome measure(s)
Primary Outcome — 10 year incidences of MACE-4(cardiovascular death, myocardial infarction, stroke and hospitalized unstable angina)
Trial sites (1)
Facility
City
Region
Status
2nd Affiliated Hospital, School of Medicine, Zhejiang University, China
Hangzhou
Zhejiang
Recruiting
More Second Affiliated Hospital, Zhejiang University, School of Medicine trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.